Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (941-950 of 1,011) with videos related to

Pageof 102
Sort By:
Journal of the American Heart Association|August 20, 2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β<sub>1</sub>-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)Sonal Singh, Helen R Warren, Timo P Hiltunen, et al.
Kidney International Reports|June 2, 2018
Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney DiseaseTaimur Dad, Kaleab Z Abebe, K Ty Bae, et al.
American Journal of Nephrology|March 31, 2021
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport SyndromeGlenn M Chertow, Gerald B Appel, Sharon Andreoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT StudyJames W Smithy, Hannah L Kalvin, Fiona D Ehrich, et al.
Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Kidney International|September 27, 2008
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndromeMark B Consugar, Wai C Wong, Patrick A Lundquist, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 16, 2020
Sorting nexin 1 loss results in increased oxidative stress and hypertensionJian Yang, Laureano D Asico, Amber L Beitelshees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal MelanomasAlvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 26, 2016
Mucormycosis in Australia: contemporary epidemiology and outcomesK J Kennedy, K Daveson, M A Slavin, et al.
Pageof 102

Showing results (941-950 of 1,011) with videos related to

Sort By:
Pageof 102
Journal of the American Heart Association|August 20, 2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β<sub>1</sub>-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)Sonal Singh, Helen R Warren, Timo P Hiltunen, et al.
Kidney International Reports|June 2, 2018
Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney DiseaseTaimur Dad, Kaleab Z Abebe, K Ty Bae, et al.
American Journal of Nephrology|March 31, 2021
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport SyndromeGlenn M Chertow, Gerald B Appel, Sharon Andreoli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT StudyJames W Smithy, Hannah L Kalvin, Fiona D Ehrich, et al.
Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Kidney International|September 27, 2008
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndromeMark B Consugar, Wai C Wong, Patrick A Lundquist, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 16, 2020
Sorting nexin 1 loss results in increased oxidative stress and hypertensionJian Yang, Laureano D Asico, Amber L Beitelshees, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal MelanomasAlvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 26, 2016
Mucormycosis in Australia: contemporary epidemiology and outcomesK J Kennedy, K Daveson, M A Slavin, et al.
Pageof 102